US2015111251A1PendingUtilityA1
Tnf-alpha binding proteins
Est. expiryDec 8, 2030(~4.3 yrs left)· nominal 20-yr term from priority
A61P 37/00A61P 3/10A61P 37/08A61P 37/02A61P 43/00A61P 37/06A61P 5/00A61P 31/00A61P 31/12A61P 31/04A61P 33/00A61P 31/02A61P 25/20A61P 35/00A61P 25/24A61P 29/00A61P 25/18A61P 25/00A61P 1/00A61P 1/04A61P 11/02A61P 1/16A61P 21/02A61P 19/02A61P 17/06A61P 11/06A61P 17/04A61P 17/00A61P 11/00A61K 51/1021C07K 2317/24C07K 2317/622C07K 2317/31A61K 39/3955C07K 2317/567C07K 2317/92A61K 45/06A61K 2039/545C07K 2317/626A61K 49/0058C07K 16/241G01N 33/6863C07K 2319/30C07K 2317/76C07K 2317/21C07K 2317/20C07K 2317/55A61K 2039/54C07K 2317/56C07K 2317/569C07K 2317/14C07K 2317/54C07K 2317/565C07K 2317/624A61K 47/6845A61K 2039/505
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
TNF-α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-α are provided. Binding proteins have high affinity for TNF-α and neutralize TNF-α activity. A binding protein can be a full-length antibody or a TNF-α-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-α binding proteins are useful for detecting TNF-α and for inhibiting TNF-α activity, including in a human subject suffering from a disease or disorder in which TNF-α activity is detrimental.
Claims
exact text as granted — not AI-modified1 - 29 . (canceled)
30 . An isolated nucleic acid encoding a binding protein or antigen binding portion thereof amino acid sequence of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, or SEQ ID NO: 46.
31 . A vector comprising the isolated nucleic acid of claim 30 .
32 . (canceled)
32 . A host cell comprising the vector of claim 31 .
33 . The host cell of claim 32 , wherein said host cell is a prokaryotic cell.
34 . The host cell of 32 , wherein said host cell is a eukaryotic cell.
35 . The host cell of claim 34 , wherein said eukaryotic cell is a protist cell, an animal cell, a plant cell, a fungal cell, a mammalian cell, an avian cell, or an insect cell.
36 . The host cell of claim 35 , wherein said eukaryotic cell is S. cerevisiae , CHO cell, COS cell, or SF9 cell.
37 . A method of producing a protein capable of binding TNF-α, the method comprising the steps of culturing the host cell of claim 32 in culture medium under conditions sufficient to produce a binding protein capable of binding TNF-α.
38 - 53 . (canceled)
54 . The vector of claim 31 , wherein said vector is pcDNA, pTT, pTT3, pEFBOS, pBV, pJV, pHybE, or pBJ.Join the waitlist — get patent alerts
Track US2015111251A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.